Johnson & Johnson Submits Schizophrenia Drug CAPLYTA sNDA to FDA Based on Positive Relapse Prevention Data

Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced the submission of a supplemental New Drug Application/sNDA to the US FDA for its schizophrenia drug called CAPLYTA (lumateperone). The submission is based on long-term Phase 3 clinical data demonstrating CAPLYTA’s safety and efficacy in preventing relapse in adults with schizophrenia.

The Phase 3, double-blind, multicenter, placebo-controlled, and randomized withdrawal trial showed compelling results. The primary endpoint indicated that the time to relapse during the 26-week double-blind treatment phase was significantly longer in patients receiving CAPLYTA compared to those on placebo (p=0.0002).

Johnson & Johnson Submits Schizophrenia Drug CAPLYTA sNDA to FDA Based on Positive Relapse Prevention Data

A smiling baby with an array of baby care products in the foreground.

Schizophrenia is a complex and chronic brain disorder affecting an estimated 2.8 million adults in the US, yet ~40% of those affected do not receive adequate care. Relapses are characterized by a recurrence of symptoms and can disrupt lives, undo treatment progress, and increase the risk of hospitalization. On average, an adult with schizophrenia experiences 9 relapses in less than 6 years.

Johnson & Johnson (NYSE:JNJ) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.

While we acknowledge the potential of JNJ to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.